Dublin, April 02, 2021 (GLOBE NEWSWIRE) -- The "Biomarkers: Technologies and Global Markets 2021" report has been added to ResearchAndMarkets.com's offering.
This new report, Biomarkers: Technologies and Global Markets, provides a comprehensive analysis of the biomarkers market in a global context, including market forecasts and sales through 2025. The report analyzes the market, segmenting it into various product offerings (i.e., instruments, consumables [reagents, kits and panels], services and software). Segmentation also provides analysis by popular technology type (genomics, proteomics and metabolomics, imaging and bioinformatics).
This study surveys the biomarker market by therapeutic area (cancer, cardiovascular and metabolic diseases, infectious diseases, neurodegenerative diseases, autoimmune diseases and others. End-users include academic institutes, pharma and biotechnology companies, clinical research organizations, hospitals and diagnostics. Geographic regions include North America, Europe and Emerging markets. Emerging markets include countries like India, China, Korea, Taiwan, Africa, Australia, New Zealand, Canada, Latin America, etc.
This report features new product developments and patents that are boosting global growth in this market.
This report provides comprehensive profiles of market players in the industry. The industry structure chapter focuses on changing market trends, market players and leading products. This chapter also covers mergers and acquisitions and other collaborations or partnerships that are expected to shape the industry.
Strengths, weaknesses, threats and opportunities are expected to play a role in the diagnostic biomarkers market. These are evaluated in detail.
The scope of the report excludes in vitro diagnostic products and regulatory aspects. Digital biomarkers are not covered in this report.
Report Includes:
- 48 data tables and 25 additional tables
- An updated review and current landscape of the global biomarkers market
- Analyses of the global market trends, with data from 2018-2020, and projections of compound annual growth rates (CAGRs) through 2025
- Estimation of market size and market potential for global biomarkers market, and corresponding market share analysis by product type, technology type, therapeutic area, end-user and geographic region for each market segment
- Latest information on market opportunities and drivers, industry structure, regulatory frameworks, clinical trials and technological updates which are affecting the overall market growth
- Identification of the leading biotechnology companies poised to introduce products during the forecast period, their impact on the face of the competitive environment and research priorities
- Encompassing details of major types of biomarkers and their use in clinical trial assessment, drug discovery and development, and therapeutics
- Review of patents issued for biomarker technologies and deep dive of the patent data by year, technology type, application, company, assignee and applicant country
- Profile description of major market players, including Abbott Laboratories Ltd., Bayer AG, Bio-Rad Laboratories Inc., Canon Medical Corp., and Luminex Corp.
Biomarkers, the biological indicators of health and disease, have come a long way, from being used as simple measurements of clinical diagnosis, to becoming essential tools in the clinical space and drug discovery and development. The utility of biomarkers has been expanding over the last couple of decades, due to the potential for predicting disease diagnosis and prognosis, treatment response, pharmacokinetics of drugs and monitoring therapy. During the COVID-19 pandemic, boosted R&D for novel diagnostics led to the approval of many biomarker-based diagnostic tests for early and rapid detection of the SARS-CoV-2 virus.
Pharmaceutical and biopharmaceutical drug developers struggle to overcome escalating cost barriers and high drug attrition rates in late-stage clinical trials. Biomarkers are promising tools to address drug development challenges. offering the prediction of drug toxicity and efficacy in early stages. The 21st Century Act allowed the Food and Drug Administration (FDA) to publish guidelines for Biomarker Qualification for use in drug development programs, paving the way for biomarker inclusion into drug development through either the drug approval process or the Biomarker Qualification Program.
Biomarkers are extremely useful in clinical trials, increasingly used to identify populations for a study, monitor therapeutic response and identify side effects. There is an emerging market of clinical research organizations (CROs) carrying out clinical trial recruitment and other services, while expanding technical expertise in bioanalytical and biomarker development. This enables pharmaceutical clients access to biomarker discovery and development.
The global biomarkers market is growing at a significant pace, driven by an explosion of publications and clinical trials. Enhanced analytical methods and the development of new, sophisticated and sensitive multiplex methods in gene expression analysis, proteomics, metabolomics and transcriptomics bring huge momentum to this market. The development of multi-biomarker assays, novel immunoassays and multi-modal imaging and mass spectrometry methods further drive market growth.
Collaborations and strategic partnerships, mergers and acquisitions and other deals between private and public players are on the rise. Companies are strengthening technical know-how and expanding product portfolios in order to offer enhanced services and new offerings to the biomarker research community. Precision medicine, particularly in the field of cancer, has contributed tremendously to an interest in biomarkers, with growing adoption of biomarkers in companion diagnostics and selecting targeted patient populations for high-value drugs. Other therapeutic areas, such as cardiovascular, neurodegenerative and autoimmune diseases are getting noticeable attention in biomarker research.
Challenges for this market, remain in the form of disparity in biomarker definitions at an international level and lack of any defined regulatory guidance for use in R&D. There is still a need to develop sensitive and robust methods of analysis for low concentration analytes via methods that can be validated. Lack of skilled manpower and the high cost of technology are other challenging factors.
Positive approaches in biomarker research, effective dialogue and collaborations between all stakeholders is expected to address challenges and take this market forward in coming years.
Key Topics Covered:
Chapter 1 Introduction
- Study Goals and Objectives
- Reasons for Doing This Study
- Scope of Report
- Information Sources
- Methodology
- Geographic Breakdown
- Analyst's Credentials
- Custom Research
- Related Reports
Chapter 2 Summary and Highlights
- Key Highlights
Chapter 3 Market and Technology Background
- Definitions of Biomarkers
- Classification of Biomarkers
- Examples of Biomarkers
- Surrogate Biomarkers/Endpoints
- Types of Biomarkers
- Molecular Biomarkers
- Imaging Biomarkers
- Biomarker Discovery, Verification and Validation
- Biomarker Discovery and Development
- Biomarker Verification
- Biomarker Validation
- Clinical Implementation
- Biomarker Qualification
- Technologies Used in Biomarker Analysis
- Genomics
- Proteomics
- Metabolomics
- Imaging
- Bioinformatics
- Applications of Biomarkers
- Diagnostics, Therapeutics and Disease Monitoring
- Drug Discovery and Development
- Clinical Trials
- Personalized Medicine
Chapter 4 Market Breakdown by Product Type
- Market by Biomarker Product Type
- Market Overview
- Market Revenue
- Market Share
- Market for Biomarker Products by Region
- Market Shares
- Instruments
- Consumables
- Services
- Software
Chapter 5 Market Breakdown by Technology Type
- Biomarker Market by Technology Type
- Market Overview
- Market Revenue
- Market Share
- Genomics
- Proteomics
- Metabolomics
- Imaging
- Bioinformatics
Chapter 6 Market Breakdown by Therapeutic Area
- Market by Therapeutic Area
- Market Overview
- Market Revenue
- Market Share
- Cancer
- Cardiovascular and Metabolic Diseases
- Infectious Diseases
- Neurodegenerative Diseases
- Autoimmune Diseases
- Other Diseases
Chapter 7 Market Breakdown by End User
- Market by Biomarker End-User
- Market Overview
- Market Revenue
- Market Share
- Academic Institutes
- Pharma and Biotechnology Companies
- Clinical Research Organizations (CROs)
- Hospitals and Diagnostics
Chapter 8 Industry Structure
- Industry Trends
- Collaborations and Partnerships
- License Agreements
- Mergers and Acquisitions
- Leading Manufacturers/Suppliers of Biomarkers Technologies
- Genomics
- Proteomics
- Metabolomics
- Imaging
- Bioinformatics
Chapter 9 Clinical Trials
- Clinical Trials by Therapeutic Area
- Clinical Trials by Study Status
- Clinical Trials by Study Phase
- Clinical Trials of Studies including Children
- Clinical Trials by Country
- Clinical Trials by Sponsor
Chapter 10 Patent Analysis
- Patents on Biomarkers
- Case Studies
- Case Study: Association for Molecular Pathology v. Myriad Genetics Inc.
- Case Study: Roche Molecular Systems Inc. v. Cepheid
- Patent Analysis
- Patents by Year
- Patents by Type
- Patents by Application
- Patents by Company
- Patents, by Country
- Patents by Type of Assignee
Chapter 11 Analysis of Market Opportunities
- Strengths of the Biomarker Market
- Rising Incidence of Diseases
- Drug Development Costs and Failures
- Advances in Omics and Imaging Technologies
- Support from Regulatory Agencies
- Collaborations and Partnerships
- Challenges in the Biomarker Market
- Technological Challenges
- Regulatory Challenges
- Requirement of Skilled Labor
- High Development Cost of Biomarkers
- Reimbursement Challenges
- Opportunities in the Biomarker Market
- Emerging Markets
- Personalized Medicine
- Innovation in Technology
- Funding and Research Initiatives
- Threats to the Biomarker Market
- Competition
- Regulatory and Reimbursement Challenges
- COVID-19 Pandemic
Chapter 12 Company Profiles
- 10X Genomics
- Abbott Laboratories Ltd.
- Abcam Plc
- Agilent Technologies Inc.
- Bayer Ag
- Beckman Coulter Life Sciences
- Becton Dickinson & Co.
- Biolegend
- Bio-Rad Laboratories Inc.
- Bio-Techne Corp.
- Bruker Corp.
- Canon Medical Systems Corp.
- Cepheid
- Creative Proteomics
- Cubresa Inc.
- Cytiva
- Danaher Corp.
- Fujifilm Visual Sonics Inc.
- GE Healthcare
- F Hoffmann-La Roche Ag
- Illumina Inc.
- Integrated DNA Technologies (IDT)
- Jeol Ltd.
- Koninklijke Philips N.V.
- Lantheus Medical Imaging Inc.
- Leco Corp.
- Leica Biosystems
- Luminex Corp.
- Metabolon Inc.
- Millipore Sigma
- Molecular Devices
- Oxford Nanopore Technologies Ltd.
- Pacific Biosciences Inc.
- Perkinelmer Inc.
- Promega Corp.
- Qiagen N.V.
- Quanterix Corp.
- Sciex
- Siemens Healthineer Ag
- Shimadzu Corp.
- Thermo Fisher Scientific Inc.
- Waters Corp.
Chapter 13 Appendix: Abbreviations/Acronyms
For more information about this report visit https://www.researchandmarkets.com/r/xjd6q0